NO960545L - Behandling av skadelige virkninger i forbindelse med administrering av ekstracellulært hemoglobin - Google Patents
Behandling av skadelige virkninger i forbindelse med administrering av ekstracellulært hemoglobinInfo
- Publication number
- NO960545L NO960545L NO960545A NO960545A NO960545L NO 960545 L NO960545 L NO 960545L NO 960545 A NO960545 A NO 960545A NO 960545 A NO960545 A NO 960545A NO 960545 L NO960545 L NO 960545L
- Authority
- NO
- Norway
- Prior art keywords
- administration
- effects associated
- treatment
- adverse effects
- extracellular hemoglobin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10613893A | 1993-08-13 | 1993-08-13 | |
PCT/IB1994/000239 WO1995005167A2 (fr) | 1993-08-13 | 1994-08-09 | Traitement des effets indesirables associes a l'administration d'hemoglobine extracellulaire |
Publications (2)
Publication Number | Publication Date |
---|---|
NO960545D0 NO960545D0 (no) | 1996-02-12 |
NO960545L true NO960545L (no) | 1996-02-29 |
Family
ID=22309699
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO960545A NO960545L (no) | 1993-08-13 | 1996-02-12 | Behandling av skadelige virkninger i forbindelse med administrering av ekstracellulært hemoglobin |
Country Status (8)
Country | Link |
---|---|
US (1) | US5750132A (fr) |
EP (2) | EP0717619A1 (fr) |
JP (1) | JPH09501441A (fr) |
AU (2) | AU7194694A (fr) |
CA (1) | CA2167716A1 (fr) |
IS (1) | IS4198A (fr) |
NO (1) | NO960545L (fr) |
WO (1) | WO1995005167A2 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08511279A (ja) * | 1994-03-28 | 1996-11-26 | バクスター、インターナショナル、インコーポレイテッド | 血管閉鎖の治療におけるヘモグロビンの治療的使用 |
US6894150B1 (en) | 1999-10-01 | 2005-05-17 | Ross Walden Tye | Non-pyrogenic, endotoxin-free, stroma-free tetrameric hemoglobin |
FR2809624B1 (fr) * | 2000-05-31 | 2002-08-02 | Centre Nat Rech Scient | Utilisation comme substitut sanguin d'une hemoglobine extracellulaire de poids moleculaire eleve |
US7504377B2 (en) * | 2006-10-23 | 2009-03-17 | Ikor, Inc. | Nitric oxide-blocked cross-linked tetrameric hemoglobin |
US7494974B2 (en) * | 2006-10-24 | 2009-02-24 | Ikor, Inc. | Carboxymethylated cross-linked tetrameric hemoglobin |
WO2010128159A1 (fr) * | 2009-05-07 | 2010-11-11 | Hemarina | Nouvelle hémoglobine et ses utilisations |
CA2849448C (fr) * | 2011-09-06 | 2020-03-24 | Bing Lou Wong | Administration orale pour des transporteurs d'oxygene a base d'hemoglobine |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1579818A (en) * | 1977-06-07 | 1980-11-26 | Yamanouchi Pharma Co Ltd | Nifedipine-containing solid preparation composition |
US4291015A (en) * | 1979-08-14 | 1981-09-22 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing a vasodilator |
US4529719A (en) * | 1983-05-04 | 1985-07-16 | Tye Ross W | Modified crosslinked stroma-free tetrameric hemoglobin |
US5043358A (en) * | 1986-03-04 | 1991-08-27 | Bristol-Myers Squibb Company | Gastroprotective process |
US4965065A (en) * | 1986-04-29 | 1990-10-23 | Bristol-Myers Squibb Company | Gastroprotective process and compositions |
US4826811A (en) * | 1986-06-20 | 1989-05-02 | Northfield Laboratories, Inc. | Acellular red blood cell substitute |
EP0561245A1 (fr) * | 1987-05-16 | 1993-09-22 | Somatogenetics International, Inc. | Produits de remplacement du sang comprenant d'hémoglobine recombinante |
GB8711614D0 (en) * | 1987-05-16 | 1987-06-24 | Medical Res Council | Proteins |
NL8901174A (nl) * | 1989-05-10 | 1990-12-03 | Het Hoofd Van De Afdeling Mili | Hemoglobine-preparaat en gebruik daarvan. |
US5545727A (en) * | 1989-05-10 | 1996-08-13 | Somatogen, Inc. | DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin |
US5173426A (en) * | 1989-10-06 | 1992-12-22 | Yale University | DNAs encoding genetically engineered low oxygen affinity mutants of human hemoglobin |
US5478806A (en) * | 1989-11-22 | 1995-12-26 | Enzon, Inc. | Enhancement of antitumor therapy with hemoglobin-based conjugates |
NZ237827A (en) * | 1990-04-16 | 1994-03-25 | Strohtech Inc | Pure globin chain or haem-binding fragment thereof and methods for its production |
WO1992011283A1 (fr) * | 1990-12-20 | 1992-07-09 | The University Of Alabama Research Foundation | Hemoglobine transgenique reticulee |
US5295944A (en) * | 1991-05-14 | 1994-03-22 | Dana-Farber Cancer Institute | Method for treating a tumor with ionizing radiation |
WO1992020369A1 (fr) * | 1991-05-14 | 1992-11-26 | Dana Farber Cancer Institute | Utilisation d'hemoglobine dans un procede de traitement de tumeurs a l'aide d'agents chimiotherapeutiques |
US5624823A (en) * | 1991-11-22 | 1997-04-29 | The General Hospital Corporation | DNA encoding procine interleukin-10 |
-
1994
- 1994-08-04 IS IS4198A patent/IS4198A/is unknown
- 1994-08-09 EP EP94921781A patent/EP0717619A1/fr not_active Withdrawn
- 1994-08-09 AU AU71946/94A patent/AU7194694A/en not_active Abandoned
- 1994-08-09 JP JP7506848A patent/JPH09501441A/ja active Pending
- 1994-08-09 WO PCT/IB1994/000239 patent/WO1995005167A2/fr not_active Application Discontinuation
- 1994-08-09 CA CA002167716A patent/CA2167716A1/fr not_active Abandoned
- 1994-08-09 EP EP97101811A patent/EP0784983A3/fr not_active Withdrawn
-
1995
- 1995-05-26 US US08/451,370 patent/US5750132A/en not_active Expired - Lifetime
-
1996
- 1996-02-12 NO NO960545A patent/NO960545L/no not_active Application Discontinuation
-
1998
- 1998-06-11 AU AU70110/98A patent/AU7011098A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU7011098A (en) | 1998-07-30 |
IS4198A (is) | 1995-02-14 |
CA2167716A1 (fr) | 1995-02-23 |
NO960545D0 (no) | 1996-02-12 |
WO1995005167A2 (fr) | 1995-02-23 |
US5750132A (en) | 1998-05-12 |
JPH09501441A (ja) | 1997-02-10 |
EP0784983A2 (fr) | 1997-07-23 |
EP0784983A3 (fr) | 2001-03-21 |
WO1995005167A3 (fr) | 1995-04-13 |
EP0717619A1 (fr) | 1996-06-26 |
AU7194694A (en) | 1995-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69129800T2 (de) | Behandlung von menschlichen retrovirus-infektionen mit 2',3'-dideoxyinosin | |
NO20050807L (no) | Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser | |
ATE233738T1 (de) | Kleine moleküle anwendbar in der behandlung von entzündgskrankheiten | |
NO960899L (no) | Fremgangsmåte for regulering av gastrointestinal motilitet | |
NO954996D0 (no) | Anvendelse av nona- og dekapeptider for fremstilling av et legemiddel for behandling av AIDS | |
WO1999013875A8 (fr) | Utilisation de nitroxydes dans le traitement de l'hypertension essentielle | |
AU2003239393A1 (en) | Intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases | |
SG152271A1 (en) | Immunemodulating oligosaccharides | |
DK1005358T3 (da) | Anvendelse af et neurturinprotein-produkt til forebyggelse og behandling af hørenedsættelse | |
NO20006604L (no) | Fremgangsmåter og transdermale sammensetninger for lindring av smerte | |
CA2071629A1 (fr) | Utilisation de substances sensibilisantes a l'insuline pour le traitement de l'hypertension | |
NO951761L (no) | Stabilt preparat for behandling av blodkoagulasjonssykdommer | |
NO994275L (no) | Nikotinsyrepreparater til behandling av hyperlipidemi og tilknyttede fremgangsmaater | |
ATE141792T1 (de) | Verwendung von carbamazepine und oxcarbazepine zur behandlung von parkinson und den parkinson- syndromen | |
DE69526937T2 (de) | Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen | |
SI1572167T1 (sl) | Transdermalni buprenorfinski dozirni reĹľim za analgezijo | |
NO960545L (no) | Behandling av skadelige virkninger i forbindelse med administrering av ekstracellulært hemoglobin | |
NO994165L (no) | Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet | |
MX9706957A (es) | Composicion que contiene amlodipina, o una sal, o felodipina y un inhibidor de enzima convertidora de angiotensina. | |
HUP0203682A2 (hu) | Eljárás foszfodiészteráz-4 inhibitor beadására | |
PH30665A (en) | Aminosulfonyl urea acat inhibitors | |
NO20044481L (no) | Azabisykliske, azatrisykliske og azaspirosykliske derivater av aminosykloheksan-NMDA, -5HT3 og neuronale nikotinreseptorantagonister. | |
DK1156795T3 (da) | Anvendelse af ravsyre eller salte deraf, og fremgangsmåde til behandling af insulinresistens | |
CA3237885A1 (fr) | Traitement de la depression resistante au traitement avec de la psilocybine | |
JO1917B1 (en) | A different method for controlling high levels of bilirubin in the blood in newborns |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |